Screened 2026-08-26 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
10x Genomics, Inc. holds its Accumulation at $64.26. Consolidating, no directional conviction, held for 117 days.
As held on the ledger · 2026-08-26
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 117 days
Price at the screen
$64.26
Valuation
N/A trailing · 316.04 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.04
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
8.10%
Below 33%
Interest-bearing debt is just 8.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.75%
Below 33%
Cash held in interest-bearing accounts and securities is 4.7% of assets, under the one-third limit.
Pass
Receivables
50.03%
Below 49%
Money owed to the company is 50.0% of assets, above the 49% limit.
Fail
Revenue purity
3.12%
Below 5%
Only 3.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-26 screen. The gold marker is the market price at the same screen. The price runs 50.0% above the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits −22% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Single cell tools priced at twice fair value
Picture a researcher paying top dollar for single cell kits while sales shrink and losses mount. 10x Genomics fails our valuation screen outright. The shares sit at $43.74 against a fair value of $21.87, a 50 percent gap that leaves no margin of safety and an opportunity rating of none.
Forward earnings trade at 211.6 times while revenue fell 3 percent and the firm posted a 4 percent profit margin alongside negative 3 percent return on equity. The ethical screen clears, yet the numbers show a business priced for rapid growth that has already turned negative.
Thirteen analysts still lean buy with a $40 median target, but that optimism sits well above our fair value and ignores the weak growth and thin returns. Cyclical or not, paying this premium leaves little room for error. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TXG trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-15Markup · changed$52.03+80.4%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 80.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 57% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 173%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (13 analysts) rates it buy, with a mean price target of $25.
2026-07-18Accumulation$28.84+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 57% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 173%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (13 analysts) rates it buy, with a mean price target of $25.
2026-07-03Accumulation$28.84+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$28.84Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
